Epidemiology of arterial hypertension in renal transplant patients:: changes over the last decade

被引:55
作者
Campistol, JM
Romero, R
Paul, J
Gutiérrez-Dalmau, A
机构
[1] Univ Barcelona, Hosp Clin Barcelona, Renal Transplant Unit, E-08036 Barcelona, Spain
[2] Complexo Hosp Univ Santiago, Dept Nephrol, Santiago De Compostela, Spain
[3] Hosp Miguel Servet, Dept Nephrol, Zaragoza, Spain
关键词
angiotensin converting enzyme inhibitors; arterial hypertension; cyclosporine; cardiovascular mortality; graft survival;
D O I
10.1093/ndt/gfh1018
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Arterial hypertension is a common clinical problem in renal transplantation, with important consequences on graft and patient survival. Patients and methods. A total of 3365 adult patients transplanted in 1990 (N = 824), 1994 (N = 1075) and 1998 (N = 1466) with a functioning graft after the first year were included. In this study, arterial hypertension was defined as systolic blood pressure (SBP) greater than or equal to140 mmHg and/or diastolic blood pressure (DBP) greater than or equal to90 mmHg and/or treatment with antihypertensive drugs. The use of angiotensin converting enzyme (ACE) inhibitors or angiotensin II (ATII) receptor blockers during the first year was recorded. Results. The prevalence of hypertension showed a progressive and significant increase during follow-up after renal transplantation in the three periods analysed, although SBP and DBP were lower in patients who underwent transplantation in 1998. The presence of arterial hypertension at 1 year was significantly associated with recipient gender (male), donor age ( <60 years), immunosuppressive therapy (cyclosporine), serum creatinine and year of transplantation. Arterial hypertension was not associated with graft survival and cardiovascular mortality. The prevalence and severity of hypertension was significantly lower in patients treated with tacrolimus vs cyclosporine. The use of ACE inhibitors or ATII receptor blockers has increased in the recent years. Conclusions. Arterial hypertension remained a common problem in renal transplantation, although in recent years the intensity of the control seems satisfactory. The use of ACE inhibitors or ATII receptor blockers has increased significantly in the last years.
引用
收藏
页码:62 / 66
页数:5
相关论文
共 16 条
[1]   Calcium channel Blockers as the treatment of choice for hypertension in renal transplant recipients: Fact or fiction [J].
Baroletti, SA ;
Gabardi, S ;
Magee, CC ;
Milford, EL .
PHARMACOTHERAPY, 2003, 23 (06) :788-801
[2]   Delayed graft function may not adversely affect short-term renal allograft outcome [J].
Browne, BJ ;
Holt, CO ;
Emovon, OE .
CLINICAL TRANSPLANTATION, 2003, 17 :35-38
[3]   Effect of calcium channel antagonist diltiazem and calcium ionophore A23187 on cyclosporine A-induced apoptosis of renal tubular cells [J].
Cheng, CH ;
Hsieh, CL ;
Shu, KH ;
Chen, YL ;
Chen, HC .
FEBS LETTERS, 2002, 516 (1-3) :191-196
[4]   Hypertensinogenic mechanism of the calcineurin inhibitors [J].
Curtis, JJ .
CURRENT HYPERTENSION REPORTS, 2002, 4 (05) :377-380
[5]   Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients [J].
Del Castillo, D ;
Campistol, JM ;
Guirado, L ;
Capdevilla, L ;
Martínez, JG ;
Pereira, P ;
Bravo, J ;
Pérez, R .
KIDNEY INTERNATIONAL, 1998, 54 :S135-S139
[6]   Long-term kidney transplant survival [J].
Hariharan, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (06) :S44-S50
[7]  
Hausberg M, 2001, Ann Transplant, V6, P31
[8]  
Iñigo P, 2001, J AM SOC NEPHROL, V12, P822, DOI 10.1681/ASN.V124822
[9]  
Kasiske BL, 2000, SEMIN NEPHROL, V20, P176
[10]   Cardiovascular disease and the renal transplant recipient [J].
Kendrick, E .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (06) :S36-S43